Reports
Sale
Australia and New Zealand Cutaneous T-cell Lymphoma Market: By Disease Type: Mycosis Fungoides (MF), Sezary Syndrome (SS); By Treatment Type: Radiation Therapy, Stem Cell Transplantation, Topical Chemotherapy, Chemotherapy, Immunotherapy; By Disease Stage; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Australia and New Zealand Cutaneous T-cell Lymphoma Market Outlook
The Australia and New Zealand cutaneous T-cell lymphoma market size is expected to grow at a CAGR of 11.3% during the forecast period of 2024-2032, driven by the increasing incidence of the condition across the region, along with surge in research activities to offer personalised solutions.
Australia and New Zealand Cutaneous T-cell Lymphoma Market Overview
Cutaneous T-cell lymphoma is a rare type of blood cancer that occurs in the white cells of the body called T-cells. It is subdivided into two major categories, namely mycosis fungoides and Sezary syndrome. It can cause rash-like redness or scaly patches on the skin. In Australia, blood cancer is one of the most common types of cancer accounting for 12% of all cancer cases in 2023. Approximately 19,500 people are expected to be diagnosed with the condition. The cutaneous T-cell lymphoma prevalence increases with age (mid-50s is a median age of disease diagnosis), indicating that the geriatric population is at a higher risk. Males are more susceptible to develop the disease.
The Australia and New Zealand cutaneous T-cell lymphoma market growth is driven by increasing prevalence of using latest and innovative technologies to boost the development of effective treatment solutions. In addition, the surge in merger and acquisition activity to meet the rising demand and provide customized solutions to the patients is fueling the market growth as well.
Increase in Research and Development Activities to Meet the Rising Australia and New Zealand Cutaneous T-cell Lymphoma Market Demand
With advancements in gene therapy and biotechnology, along with a deeper understanding of human physiology, there is a significant emphasis on developing effective and targeted therapies to treat the disease. In December 2023, Innate Pharma SA presented positive data, supporting the use of lacutamab to treat Sezary Syndrome (a subtype of cutaneous T-cell lymphoma). As per the results of Phase 2 TELLOMAK trial, lacutamab, the first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody was found safe and effective with an overall response rate of 46.4% on the skin.
In September 2023, KT-333 , a treatment for relapsed/refractory cutaneous T-cell lymphoma also gained a fast-track designation from the FDA. The novel treatment is based on degrading the STAT3 protein, which has been historically undruggable for treating the condition.
Rising Adoption of Innovative Alternatives to Drive Australia and New Zealand Cutaneous T-cell Lymphoma Market Size
In December 2023, Soligenix, Inc., a late-stage biopharmaceutical company, described the potential use of HyBryte™ to treat cutaneous T-cell lymphoma (CTCL). HyBryte ™ is a first-in-class photodynamic therapy with synthetic hypericin as a potential photosensitizer that is applied topically on skin lesions. It reaches deep within the skin and also prevents the chances of secondary malignancies (including melanoma), which are commonly associated with frequently administering DNA damaging drugs. When used in treating CTCL, the new treatment option demonstrated effectiveness along with safety and catered to a broad section of patients, including different lesion types, different skin tones and different disease stages.
Key Companies Expanding Their Product Portfolios with Surge in Merger and Acquisition Activity
With the rising convergence of new technologies into drug development, Australia and New Zealand cutaneous T-cell lymphoma market share is likely to grow further in the forecast period. In January 2024, AstraZeneca announced their plan to acquire Gracell Biotechnologies, a clinical-stage biopharmaceutical company specializing in cell therapies for cancer, in a deal expected to cost around USD 1.2 billion. The acquisition is poised to expand AstraZeneca’s pipeline of cell therapies and manufacture potential new treatment for multiple tumours and autoimmune diseases in coming years.
Australia and New Zealand Cutaneous T-cell Lymphoma Market Segmentation
Market Breakup by Disease Type
- Mycosis Fungoides (MF)
- Sezary Syndrome (SS)
Market Breakup by Treatment Type
- Radiation therapy
- Stem Cell Transplantation
- Topical Chemotherapy
- Chemotherapy
- Immunotherapy
Market Breakup by Disease Stage
- Early-Stage (Limited) CTCL
- Advanced-Stage (Advanced) CTCL
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centres
Market Breakup by Country
- Australia
- New Zealand
Australia and New Zealand Cutaneous T-cell Lymphoma Market Regional Analysis
With a robust healthcare infrastructure and surge in research and development activities to expedite drug development process, Australia is poised to lead the Australia and New Zealand cutaneous T-cell lymphoma market share in the forecast period. The rising collaborations between research institutions and prominent healthcare companies are poised to add significant market value to the region.
New Zealand is also predicted to experience significant growth owing to the emphasis on improving healthcare infrastructure and the rising awareness about the importance of providing effective solutions to the rising geriatric population in the region. Medical regulatory authorities like Medsafe are continuously approving new drugs to provide quality care to the patients. Moreover, a surge in foreign investments to leverage academic talent along with easily available resources is a major factor boosting market growth.
Australia and New Zealand Cutaneous T-cell Lymphoma Market: Competitor Landscape
In October 2023, Citius Pharmaceuticals, Inc. announced the acquisition of TenX Keane to establish Citius Oncology, Inc. focused entirely on developing and commercialising oncology therapies. Citius’s, LYMPHIR, a potential treatment for recurring cutaneous T-cell lymphoma is seeking approval from the regulatory authorities. The drug is estimated to exceed a market value of USD 400 million and emerge as a unique IL-2 receptor targeted therapy for the disease. The market has been witnessing continuous mergers and acquisitions to expand their services and expediate the drug development process.
The key features of the Australia and New Zealand cutaneous T-cell lymphoma market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Mylan N.V. (now part of Viatris)
- Celgene Corporation (now part of Bristol Myers Squibb)
- Takeda Pharmaceutical Company Limited
- Mundipharma International Limited
- Novartis AG
- Kyowa Kirin Co., Ltd.
- Incyte Corporation
- Bristol Myers Squibb
- Eli Lilly and Company
- Genentech, Inc. (a member of the Roche Group)
- Seattle Genetics, Inc.
- Almirall, S.A.
- Eisai Co., Ltd.
- Karyopharm Therapeutics Inc.
- Leo Pharma A/S
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Treatment Type |
|
| Breakup by Disease Stage |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Australia and New Zealand Cutaneous T-cell Lymphoma Market Overview
3.1 Australia and New Zealand Cutaneous T-cell Lymphoma Market Historical Value (2017-2023)
3.2 Australia and New Zealand Cutaneous T-cell Lymphoma Market Forecast Value (2024-2032)
4 Australia and New Zealand Cutaneous T-cell Lymphoma Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.3 Porter’s Five Forces Model
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Australia and New Zealand Cutaneous T-cell Lymphoma Market Segmentation
5.1 Australia and New Zealand Cutaneous T-cell Lymphoma Market by Disease Type
5.1.1 Market Overview
5.1.2 Mycosis Fungoides (MF)
5.1.3 Sezary Syndrome (SS)
5.2 Australia and New Zealand Cutaneous T-cell Lymphoma Market by Treatment Type
5.2.1 Market Overview
5.2.2 Radiation therapy
5.2.3 Stem Cell Transplantation
5.2.4 Topical Chemotherapy
5.2.5 Chemotherapy
5.2.6 Immunotherapy
5.3 Australia and New Zealand Cutaneous T-cell Lymphoma Market by Disease Stage
5.3.1 Market Overview
5.3.2 Early-Stage (Limited) CTCL
5.3.3 Advanced-Stage (Advanced) CTCL
5.4 Australia and New Zealand Cutaneous T-cell Lymphoma Market by End User
5.4.1 Market Overview
5.4.2 Hospitals
5.4.3 Specialty Clinics
5.4.4 Ambulatory Surgical Centres
5.5 Australia and New Zealand Cutaneous T-cell Lymphoma Market by Country
5.5.1 Market Overview
5.5.2 Australia
5.5.3 New Zealand
6 Patent Analysis
6.1 Analysis by Type of Patent
6.2 Analysis by Publication Year
6.3 Analysis by Issuing Authority
6.4 Analysis by Patent Age
6.5 Analysis by CPC Analysis
6.6 Analysis by Patent Valuation
6.7 Analysis by Key Players
7 Grants Analysis
7.1 Analysis by Year
7.2 Analysis by Amount Awarded
7.3 Analysis by Issuing Authority
7.4 Analysis by Grant Application
7.5 Analysis by Funding Institute
7.6 Analysis by NIH Departments
7.7 Analysis by Recipient Organization
8 Funding Analysis
8.1 Analysis by Funding Instances
8.2 Analysis by Type of Funding
8.3 Analysis by Funding Amount
8.4 Analysis by Leading Players
8.5 Analysis by Leading Investors
8.6 Analysis by Geography
9 Partnership and Collaborations Analysis
9.1 Analysis by Partnership Instances
9.2 Analysis by Type of Partnership
9.3 Analysis by Leading Players
9.4 Analysis by Geography
10 Regulatory Framework
10.1 Regulatory Overview
11 Supplier Landscape
11.1 Mylan N.V. (now part of Viatris)
11.1.1 Financial Analysis
11.1.2 Product Portfolio
11.1.3 Demographic Reach and Achievements
11.1.4 Mergers and Acquisitions
11.1.5 Certifications
11.2 Celgene Corporation (now part of Bristol Myers Squibb)
11.2.1 Financial Analysis
11.2.2 Product Portfolio
11.2.3 Demographic Reach and Achievements
11.2.4 Mergers and Acquisitions
11.2.5 Certifications
11.3 Takeda Pharmaceutical Company Limited
11.3.1 Financial Analysis
11.3.2 Product Portfolio
11.3.3 Demographic Reach and Achievements
11.3.4 Mergers and Acquisitions
11.3.5 Certifications
11.4 Mundipharma International Limited
11.4.1 Financial Analysis
11.4.2 Financial Portfolio
11.4.3 Demographic Reach and Achievements
11.4.4 Mergers and Acquisitions
11.4.5 Certifications
11.5 Novartis AG
11.5.1 Financial Analysis
11.5.2 Product Portfolio
11.5.3 Demographic Reach and Achievements
11.5.4 Mergers and Acquisitions
11.5.5 Certifications
11.6 Kyowa Kirin Co., Ltd.
11.6.1 Financial Analysis
11.6.2 Product Portfolio
11.6.3 Demographic Reach and Achievements
11.6.4 Mergers and Acquisitions
11.6.5 Certifications
11.7 Incyte Corporation
11.7.1 Financial Analysis
11.7.2 Product Portfolio
11.7.3 Demographic Reach and Achievements
11.7.4 Mergers and Acquisitions
11.7.5 Certifications
11.8 Bristol Myers Squibb
11.8.1 Financial Analysis
11.8.2 Product Portfolio
11.8.3 Demographic Reach and Achievements
11.8.4 Mergers and Acquisitions
11.8.5 Certifications
11.9 Eli Lilly and Company
11.9.1 Financial Analysis
11.9.2 Product Portfolio
11.9.3 Demographic Reach and Achievements
11.9.4 Mergers and Acquisitions
11.9.5 Certifications
11.10 Genentech, Inc. (a member of the Roche Group)
11.10.1 Financial Analysis
11.10.2 Product Portfolio
11.10.3 Demographic Reach and Achievements
11.10.4 Mergers and Acquisitions
11.10.5 Certifications
11.11 Seattle Genetics, Inc.
11.11.1 Financial Analysis
11.11.2 Product Portfolio
11.11.3 Demographic Reach and Achievements
11.11.4 Mergers and Acquisitions
11.11.5 Certifications
11.12 Almirall, S.A.
11.12.1 Financial Analysis
11.12.2 Product Portfolio
11.12.3 Demographic Reach and Achievements
11.12.4 Mergers and Acquisitions
11.12.5 Certifications
11.13 Eisai Co., Ltd.
11.13.1 Financial Analysis
11.13.2 Product Portfolio
11.13.3 Demographic Reach and Achievements
11.13.4 Mergers and Acquisitions
11.13.5 Certifications
11.14 Karyopharm Therapeutics Inc.
11.14.1 Financial Analysis
11.14.2 Product Portfolio
11.14.3 Demographic Reach and Achievements
11.14.4 Mergers and Acquisitions
11.14.5 Certifications
11.15 Leo Pharma A/S
11.15.1 Financial Analysis
11.15.2 Product Portfolio
11.15.3 Demographic Reach and Achievements
11.15.4 Mergers and Acquisitions
11.15.5 Certifications
12 Australia and New Zealand Cutaneous T-cell Lymphoma Market - Distribution Model (Additional Insight)
12.1 Overview
12.2 Potential Distributors
12.3 Key Parameters for Distribution Partner Assessment
13 Key Opinion Leaders (KOL) Insights (Additional Insight)
14 Company Competitiveness Analysis (Additional Insight)
14.1 Very Small Companies
14.2 Small Companies
14.3 Mid-Sized Companies
14.4 Large Companies
14.5 Very Large Companies
15 Payment Methods (Additional Insight)
15.1 Government Funded
15.2 Private Insurance
15.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 11.3% during the forecast period of 2024-2032, driven by increasing incidence of the condition across the region.
The market demand is driven by surge in investments to expedite research and development activities and develop potential drugs, along with key healthcare organisations expanding their product lines and integrating latest techniques in drug development.
Rising prevalence of using alternative therapies to provide personalised solutions to the patients is a major market trend. In December 2023, Soligenix, Inc., described the potential use of HyBryte™ to treat cutaneous T-cell lymphoma (CTCL). Containing synthetic hypericin, it is applied topically on skin lesions and demonstrated effectiveness along with safety. It catered to a broad section of patients, including different lesion types, skin tones as well as disease stages.
Based on disease types, the market is divided into mycosis fungoides (MF) and Sezary syndrome (SS).
Major end users include hospitals, speciality clinics, and ambulatory surgical centres.
Radiation therapy, stem cell transplantation, topical chemotherapy, chemotherapy, and immunotherapy are common treatment types available in the market.
It includes early-stage (limited) CTCL and advanced-stage (advanced) CTCL.
Based on country, it is divided into Australia and New Zealand.
Key players involved in the market are Mylan N.V. (now part of Viatris), Celgene Corporation (now part of Bristol Myers Squibb), Takeda Pharmaceutical Company Limited, Mundipharma International Limited, Novartis AG, Kyowa Kirin Co., Ltd., Incyte Corporation, Bristol Myers Squibb, Eli Lilly and Company, Genentech, Inc. (a member of the Roche Group), Seattle Genetics, Inc., Almirall, S.A., Eisai Co., Ltd., Karyopharm Therapeutics Inc. and Leo Pharma A/S.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2199
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 3299
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 4399
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 5499
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER